LiGeR-HN1 is a clinical research study for people with head and neck squamous cell carcinoma (HNSCC), where the cancer has spread (metastatic) or returned (recurrent).
‍
The purpose of the study is to test an investigational agent, petosemtamab*, to learn if the combination of petosemtamab and pembrolizumab works better against cancer, compared to pembrolizumab only.

LiGeR-HN2 is a clinical research study for people with head and neck squamous cell carcinoma (HNSCC), where the cancer has returned (recurrent) or spread to other parts of the body (metastatic).
‍
To participate in this study, you have to have received prior immunotherapy and platinum-based chemotherapy for your recurrent or metastatic HNSCC.
‍
The purpose of the study is to compare how the investigational agent, petosemtamab*, may work differently than approved prescription medicines (cetuximab, methotrexate, or docetaxel).